Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 1 versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 1 versus TRIOSTAT.
THYROLAR-1 vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyrolar-1 is a combination of levothyroxine (T4) and liothyronine (T3). T4 is converted to the active hormone T3 in peripheral tissues. Both forms bind to thyroid hormone receptors, which regulate gene transcription, influencing metabolism, growth, and development.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Oral: 30-60 mg liothyronine (T3) daily, typically initiated at 15 mg/day and titrated upward based on clinical response. Usual maintenance dose 25-50 mg/day.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
Levothyroxine (T4): 6–7 days; Liothyronine (T3): 1–2 days. In hyperthyroidism, T4 half-life may be reduced to 3–4 days; in hypothyroidism, prolonged to 9–10 days.
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal excretion of iodide; after deiodination of T3 and T4, iodine is excreted in urine (∼80%) and feces (∼20%).
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone